Efficacy and Safety of IL-5 Pathway-Targeting Biologics (Mepolizumab, Reslizumab, Benralizumab) in the Management of Hypereosinophilic Syndromes: A Systematic Review and Meta-Analysis. OAIJMR [Internet]. 2025 Sep. 2 [cited 2026 Aug. 19];5(5):607-26. Available from: https://hmpublisher.com/index.php/OAIJMR/article/view/780